ESR1 and breast carcinoma: The standardized assessment of estrogen receptor (ER)- (75% of breast cancer patients) and HER2-expression (25% of breast cancer patients) as predictive biomarkers enabled targeted therapy tailored to molecular breast cancer subtypes (Allison et al., 2020).